{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T23:37:53Z","timestamp":1773445073663,"version":"3.50.1"},"reference-count":132,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1053\/j.jvca.2025.02.009","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T20:06:36Z","timestamp":1738958796000},"page":"1287-1305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors"],"prefix":"10.1053","volume":"39","author":[{"given":"Paul S.","family":"Pagel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin","family":"Hang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2025.02.009_bib0001","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.009_bib0002","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for management of hypertrophic cardiomyopathy: A report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0003","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the sarcomeric hypertrophic cardiomyopathy registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.722340","article-title":"Hypertrophic cardiomyopathy: From phenotype to pathogenesis to treatment","volume":"8","author":"Cheng","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.jvca.2025.02.009_bib0005","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy. Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2025.02.009_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001620","article-title":"Nonfamilial hypertrophic cardiomyopathy: Prevalence, natural history, and clinical implications","volume":"10","author":"Ingles","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1053\/j.jvca.2025.02.009_bib0007","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1161\/CIRCULATIONAHA.121.053527","article-title":"Time to think differently about sarcomere-negative hypertrophic cardiomyopathy","volume":"143","author":"Watkins","year":"2021","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0008","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-I","article-title":"A molecular basis for familial hypertrophic cardiomyopathy: A beta cardiac myosin heavy chain gene missense mutation","volume":"62","author":"Geisterfer-Lowrance","year":"1990","journal-title":"Cell"},{"key":"10.1053\/j.jvca.2025.02.009_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.1236921","article-title":"Allele-specific silencing of mutant Myh6 transcripts in mice suppressing hypertrophic cardiomyopathy","volume":"342","author":"Jiang","year":"2013","journal-title":"Science"},{"key":"10.1053\/j.jvca.2025.02.009_bib0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41569-021-00608-2","article-title":"Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies","volume":"19","author":"Walsh","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0011","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12265-009-9131-8","article-title":"Mechanical and energetic consequences of HCM-causing mutations","volume":"2","author":"Ferrantini","year":"2009","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1053\/j.jvca.2025.02.009_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12551-017-0274-6","article-title":"Hypertrophic cardiomyopathy and the myosin mesa: Viewing an old disease in a new light","volume":"10","author":"Trivedi","year":"2018","journal-title":"Biophys Rev"},{"key":"10.1053\/j.jvca.2025.02.009_bib0013","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.jvca.2025.02.009_bib0014","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","article-title":"Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy","volume":"141","author":"Toepfer","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0015","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy. JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0016","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0735-1097(92)90135-A","article-title":"Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: Clarification of pathophysiology and importance in intraoperative decision making","volume":"20","author":"Grigg","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0017","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0018","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006657","article-title":"Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy","volume":"7","author":"Lu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.02.009_bib0019","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0020","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/01.CIR.72.4.853","article-title":"Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerate in patients with hypertrophic cardiomyopathy: Short- and long-term results","volume":"72","author":"Bonow","year":"1985","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0021","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0022","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/CIRCRESAHA.116.309348","article-title":"Hypertrophic obstructive cardiomyopathy. Septal myectomy and septal ablation","volume":"121","author":"Nishimura","year":"2017","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2025.02.009_bib0023","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjcard.2022.06.007","article-title":"Ventricular septal myectomy for obstructive hypertrophic cardiomyopathy (analysis spanning 60 years of practice): AJC Expert Panel","volume":"180","author":"Maron","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0024","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.124.069378","article-title":"Long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy: Insights from the SHARE registry","volume":"150","author":"Maurizi","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132202","article-title":"Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with hypertrophic cardiomyopathy","volume":"409","author":"Rella","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0026","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: A first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.02.009_bib0027","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.cardfail.2024.04.024","article-title":"Evolving strategies for the management of obstructive hypertrophic cardiomyopathy","volume":"30","author":"Liang","year":"2024","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0028","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40256-024-00667-z","article-title":"Novel cardiac myosin inhibitor therapy for hypertrophic cardiomyopathy in adults: A contemporary review","volume":"24","author":"Kalinski","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1053\/j.jvca.2025.02.009_bib0029","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/14656566.2024.2362902","article-title":"Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 And beyond","volume":"25","author":"Gaballa","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1053\/j.jvca.2025.02.009_bib0030","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.medj.2024.06.001","article-title":"Two cardiac myosin inhibitors in the treatment of obstructive hypertrophic cardiomyopathy","volume":"5","author":"Desai","year":"2024","journal-title":"Medicine"},{"key":"10.1053\/j.jvca.2025.02.009_bib0031","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1097\/MS9.0000000000002466","article-title":"Efficacy and safety of mavacamten for the treatment of hypertrophic cardiomyopathy: An updated systematic review and meta-analysis of randomized controlled trials","volume":"86","author":"Almansouri","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1053\/j.jvca.2025.02.009_bib0032","first-page":"e70550","article-title":"Safety and effectiveness of mavacamten use in hypertrophic obstructive cardiomyopathy: A systematic review and meta-analysis","volume":"16","author":"Alharbi","year":"2024","journal-title":"Cureus"},{"key":"10.1053\/j.jvca.2025.02.009_bib0033","doi-asserted-by":"crossref","first-page":"375","DOI":"10.31083\/j.rcm2510375","article-title":"A systematic review and meta-analysis of efficacy and safety of mavacamten for the treatment of hypertrophic cardiomyopathy","volume":"25","author":"Zheng","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"10.1053\/j.jvca.2025.02.009_bib0034","first-page":"491","article-title":"Evaluation of mavacamten in patients with hypertrophic cardiomyopathy","volume":"25","author":"Liao","year":"2024","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1053\/j.jvca.2025.02.009_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102802","article-title":"Innovative pharmacological approaches to hypertrophic cardiomyopathy: The emerging role of aficamten","volume":"49","author":"Kokori","year":"2024","journal-title":"Curr Prob Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0036","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0037","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamacardio.2024.3810","article-title":"Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction: Primary results of the EMBARK-HFpEF trial","volume":"10","author":"Shah","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0038","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1053\/j.jvca.2024.09.005","article-title":"New frontiers in hypertrophic obstructive cardiomyopathy","volume":"38","author":"Parniani","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.02.009_bib0039","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441","article-title":"Mavacamten: Real-world experience from 22 months of the Risk Evaluation and Mitigation Strategy (REMS) program","volume":"18","author":"Desai","year":"2025","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pcad.2024.02.001","article-title":"Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center","volume":"86","author":"Desai","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1053\/j.jvca.2025.02.009_bib0041","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jchf.2024.03.009","article-title":"Real-world experience and 36-week outcomes of patients with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten","volume":"12","author":"Reza","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0042","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012545","article-title":"Stop dreaming: Mavacamten REMS data are here","volume":"18","author":"Masri","year":"2025","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1429230","article-title":"One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy","volume":"11","author":"Kim","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.jvca.2025.02.009_bib0044","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/368113a0","article-title":"Single myosin molecule mechanics: Piconewton forces and nanometer steps","volume":"368","author":"Finer","year":"1994","journal-title":"Nature"},{"key":"10.1053\/j.jvca.2025.02.009_bib0045","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1053\/j.jvca.2025.02.009_bib0046","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-moleculate modulator of cardiac myosin acts on multiple stages of the myosin chemomechamical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1053\/j.jvca.2025.02.009_bib0047","doi-asserted-by":"crossref","unstructured":"Cail RC, Baez-Cruz FA, Winkelmann D, et al. Dynamics of beta-cardiac myosin between the super-relaxed and disordered-relaxed states. bioRxiv 2024;2024.12.14.628474.","DOI":"10.1101\/2024.12.14.628474"},{"key":"10.1053\/j.jvca.2025.02.009_bib0048","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3390\/cells13221913","article-title":"MYBPC3 D389V variant induces hypercontractility in cardiac organoids","volume":"13","author":"Desai","year":"2024","journal-title":"Cells"},{"key":"10.1053\/j.jvca.2025.02.009_bib0049","doi-asserted-by":"crossref","first-page":"H1112","DOI":"10.1152\/ajpheart.00325.2020","article-title":"Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue","volume":"320","author":"Sewanan","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0050","doi-asserted-by":"crossref","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","article-title":"Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory chain mouse model of hypertrophic cardiomyopathy","volume":"320","author":"Awinda","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0051","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.202012640","article-title":"Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation","volume":"153","author":"Sewanan","year":"2021","journal-title":"J Gen Physiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168407","article-title":"A small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2025.02.009_bib0053","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1053\/j.jvca.2025.02.009_bib0054","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1053\/j.jvca.2025.02.009_bib0055","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: A clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.jvca.2025.02.009_bib0056","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/00498254.2024.2389407","article-title":"In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor","volume":"54","author":"Sukhun","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1053\/j.jvca.2025.02.009_bib0057","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/00498254.2024.2381111","article-title":"Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [14C] aficamten following single oral dose administration in rats","volume":"54","author":"Grillo","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1053\/j.jvca.2025.02.009_bib0058","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","article-title":"Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy","volume":"3","author":"Hartman","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"10.1053\/j.jvca.2025.02.009_bib0059","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41598-022-26630-z","article-title":"Effects of aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy","volume":"13","author":"Sharpe","year":"2023","journal-title":"Sci Rep"},{"key":"10.1053\/j.jvca.2025.02.009_bib0060","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jvp.13103","article-title":"Pharmacokinetics of a single dose of aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model","volume":"46","author":"Sharpe","year":"2023","journal-title":"J Vet Pharmacol Ther"},{"key":"10.1053\/j.jvca.2025.02.009_bib0061","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030607","article-title":"Long-term safety and efficacy of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy: Interim results of the PIONEER-OLE study","volume":"13","author":"Masri","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.02.009_bib0062","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jacc.2022.01.005","article-title":"Assessment of disease status and treatment response with artificial intelligence-enhanced electrocardiography in obstructive hypertrophic cardiomyopathy","volume":"79","author":"Tison","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0063","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853","article-title":"Study design and rationale of EXPLORER-HCM: Evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Ho","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0064","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.02.009_bib0065","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0066","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0067","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): Health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.jvca.2025.02.009_bib0068","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0069","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/CIRCULATIONAHA.123.067470","article-title":"Association of echocardiographic parameters and health status in patients with obstructive hypertrophic cardiomyopathy: Insights from EXPLORER-HCM","volume":"150","author":"Arnold","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13696998.2021.2011301","article-title":"Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial","volume":"25","author":"Xie","year":"2022","journal-title":"J Med Econ"},{"key":"10.1053\/j.jvca.2025.02.009_bib0071","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.2737","article-title":"Effect of beta-blocker therapy on the response to mavacamten in patients with obstructive hypertrophic cardiomyopathy","volume":"25","author":"Wheeler","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0072","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1161\/CIRCULATIONAHA.123.065600","article-title":"Effect of mavacamten in women compared with men with obstructive hypertrophic cardiomyopathy: Insights from EXPLORER-HCM","volume":"149","author":"Cresci","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0073","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jchf.2023.07.030","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy with or without hypertension: Post-hoc analysis of the EXPLORER-HCM trial","volume":"12","author":"Wang","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0074","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jamacardio.2022.5099","article-title":"Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: A secondary analysis of the EXPLORER-HCM randomized trial","volume":"8","author":"Wheeler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2024.10.449","article-title":"Association between age or duration of diagnosis in obstructive hypertrophic cardiomyopathy and response to mavacamten treatment: Exploratory analysis of the EXPLORER-HCM trial","author":"Wang","year":"2024","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0076","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: Interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0077","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.033767","article-title":"Mavacamten for obstructive hypertrophic cardiomyopathy: Rationale for clinically guided dose titration to optimize individual response","volume":"13","author":"Owens","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.02.009_bib0078","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.02.009_bib0079","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjcard.2024.11.028","article-title":"A multicenter evaluation of the impact of therapies on deep learning-based electrocardiographic hypertrophic cardiomyopathy markers","volume":"237","author":"Dhingra","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.echo.2024.10.001","article-title":"Sustained benefits of mavacamten in patients with obstructive hypertrophic cardiomyopathy: Long-term assessment using artificial intelligence-electrocardiogram and echocardiographic data","volume":"38","author":"Suppah","year":"2024","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1053\/j.jvca.2025.02.009_bib0081","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2021.05.007","article-title":"Study design and rationale of VALOR-HCM: Evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy","volume":"239","author":"Desai","year":"2021","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2025.02.009_bib0082","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0083","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: Week 128 results from VALOR-HCM","author":"Desai","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0084","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: Insights from the VALOR-HCM study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.02.009_bib0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","article-title":"Mavacamten-associated temporal changes in left atrial function in obstructive HCM: Insights from the VALOR-HCM trial","volume":"18","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.02.009_bib0086","article-title":"Serial changes in ventricular strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: Insights from the VALOR-HCM trial","volume":"9","author":"Desai","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.02.009_bib0087","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jcmg.2024.02.014","article-title":"Mitral regurgitation in obstructive hypertrophic cardiomyopathy: Insight from the VALOR-HCM study","volume":"17","author":"Cremer","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.jvca.2025.02.009_bib0088","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.jacc.2020.04.017","article-title":"Lessons from MAVERiCK-HCM: The need for less speed","volume":"75","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0089","unstructured":"Bristol-Myers Squibb. A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM). https:\/\/clinicaltrials.gov\/search?cond=NCT05582395. 2023. [Accessed January 11, 2025]."},{"key":"10.1053\/j.jvca.2025.02.009_bib0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","article-title":"Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19","volume":"11","author":"Koopmans","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.1053\/j.jvca.2025.02.009_bib0091","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2217\/14622416.9.6.691","article-title":"Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China","volume":"9","author":"Chen","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1053\/j.jvca.2025.02.009_bib0092","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2003.05.009","article-title":"Prevalence of idiopathic hypertrophic cardiomyopathy in China: A population-based echocardiographic analysis of 8080 adults","volume":"116","author":"Zou","year":"2004","journal-title":"Am J Med"},{"key":"10.1053\/j.jvca.2025.02.009_bib0093","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: The EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0094","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1253\/circj.CJ-24-0501","article-title":"Phase 3 open-label study evaluating the efficacy and safety of mavacamten in Japanese adults with obstructive hypertrophic cardiomyopathy: The HORIZON-HCM study","volume":"89","author":"Kitaoka","year":"2024","journal-title":"Circ J"},{"key":"10.1053\/j.jvca.2025.02.009_bib0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.amjcard.2024.12.024","article-title":"Comparison of alcohol septal ablation with mavacamten in obstructive hypertrophic cardiomyopathy","volume":"239","author":"Samhan","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0096","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1161\/CIRCULATIONAHA.122.063383","article-title":"Can novel myosin inhibitors defer septal reduction therapy in HCM? At what risk and at what cost?","volume":"147","author":"Rakowski","year":"2023","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.009_bib0097","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jacbts.2022.04.008","article-title":"A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants","volume":"7","author":"Malik","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"10.1053\/j.jvca.2025.02.009_bib0098","article-title":"Safety, tolerability, and pharmacokinetics, and pharmacodynamics of single and multiple doses of aficamten in healthy Chinese participants: A randomized, double-blind, placebo-controlled phase 1 study","volume":"23","author":"Zhao","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0099","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0100","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cardfail.2023.07.003","article-title":"Aficamten for drug-refractory severe obstructive hypertrophic cardiomyopathy in patients receiving disopyramide: REDWOOD-HCM cohort 3","volume":"29","author":"Owens","year":"2023","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0101","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","article-title":"Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: Results from the REDWOOD-HCM trial, cohort 4","volume":"30","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0102","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jacc.2024.09.002","article-title":"Standard-of-care medication withdrawal in patients with obstructive hypertrophic cardiomyopathy receiving aficamten in FOREST-HCM","volume":"84","author":"Masri","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0103","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jacc.2024.09.015","article-title":"Cardiac myosin inhibition in obstructive hypertrophic cardiomyopathy: Can aficamten stand alone?","volume":"84","author":"Ammirati","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0104","first-page":"1993","article-title":"Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM","volume":"26","author":"Masri","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0105","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.009_bib0106","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.035993","article-title":"Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: Results from SEQUOIA-HCM","volume":"13","author":"Coats","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2025.02.009_bib0107","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.jacc.2024.08.002","article-title":"Impact of aficamten on echocardiographic cardiac structure and function in symptomatic obstructive cardiomyopathy","volume":"84","author":"Hegde","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0108","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","article-title":"Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy","volume":"84","author":"Masri","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0109","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jacc.2024.09.003","article-title":"Impact of aficamten on disease symptom burden in obstructive hypertrophic cardiomyopathy: Results from SEQUOIA-HCM","volume":"84","author":"Maron","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0110","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jacc.2024.08.014","article-title":"Effect of aficamten on health status outcomes in obstructive hypertrophic cardiomyopathy: Results from SEQUOIA-HCM","volume":"84","author":"Sherrod","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0111","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1093\/eurheartj\/ehae590","article-title":"Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: The SEQUIOA-HCM trial","volume":"45","author":"Coats","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1053\/j.jvca.2025.02.009_bib0112","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jchf.2023.10.004","article-title":"Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design","volume":"12","author":"Coats","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0113","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.jacc.2024.08.031","article-title":"Echocardiographic changes with aficamten: A pixel is worth 1,024 bits","volume":"84","author":"Desai","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0114","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.jacc.2024.08.040","article-title":"Unveiling the unseen: Myosin inhibitors cause reverse remodeling of left ventricular macrostructure and microstructure by CMR","volume":"84","author":"Rochitte","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0115","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2024.09.021","article-title":"Cardiac myosin inhibitors: Is the emperor wearing new clothes, or is it placebo?","volume":"84","author":"Rasmussen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0116","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/j.jacc.2024.08.043","article-title":"Trusting the true experts through patient-reported health status in hypertrophic cardiomyopathy","volume":"24","author":"Reza","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0117","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2024.08.064","article-title":"Aficamten in hypertrophic cardiomyopathy: Roots and branches of SEQUOIA","volume":"84","author":"Kittleson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0118","unstructured":"Cytokinetics. Phase 3 trial to evaluate the efficacy and safety of aficamten compared to metoprolol succinate in adults with symptomatic oHCM (MAPLE-HCM). https:\/\/clinicaltrials.gov\/search?cond=NCT05767346. 2024. [Accessed January 16, 2025]."},{"key":"10.1053\/j.jvca.2025.02.009_bib0119","unstructured":"Cytokinetics. Phase 3 trial to evaluate the efficacy and safety of aficamten compared to placebo in adults with symptomatic nHCM (ACACIA-HCM).https:\/\/clinicaltrials.gov\/search?cond=NCT06081894. 2024. [Accessed January 16, 2025]."},{"key":"10.1053\/j.jvca.2025.02.009_bib0120","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/j.jvca.2020.07.016","article-title":"Heart failure with preserved ejection fraction: A comprehensive review and update of diagnosis, pathophysiology, treatment, and perioperative implications","volume":"35","author":"Pagel","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.02.009_bib0121","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ejhf.1708","article-title":"Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: Implications for incident and prevalent heart failure","volume":"22","author":"Butler","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.009_bib0122","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.009_bib0123","unstructured":"Bristol-Myers Squibb. Study to evaluate safety, tolerability and drug levels of BMS-986435\/\u200bMYK-224 in participants with heart failure with preserved ejection fraction (HFpEF) (AURORA-HFpEF).https:\/\/clinicaltrials.gov\/search?cond=NCT06122779. 2024. [Accessed January 17, 2025]."},{"key":"10.1053\/j.jvca.2025.02.009_bib0124","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmccpl.2024.100075","article-title":"Roles of cMyBP-c phophylation on cardiac dysfunction in db\/db mice","volume":"8","author":"Desai","year":"2024","journal-title":"J Mol Cell Cardiol Plus"},{"key":"10.1053\/j.jvca.2025.02.009_bib0125","series-title":"Kaplan's Cardiac Anesthesia: Perioperative and Critical Care","first-page":"179","article-title":"Cardiovascular pharmacology of anesthetics","author":"Pagel","year":"2024"},{"key":"10.1053\/j.jvca.2025.02.009_bib0126","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/bja\/73.5.658","article-title":"Midazolam is metabolized by at least three different cytochrome P450 enzymes","volume":"73","author":"Wandel","year":"1994","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2025.02.009_bib0127","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1213\/00000539-199305000-00022","article-title":"Human alfentanil metabolism by cytochrome P450 3A3\/4. An explanation for the interindividual variability in alfentanil clearance?","volume":"76","author":"Kharasch","year":"1993","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2025.02.009_bib0128","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/cp.1999.v66.100038001","article-title":"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study","volume":"66","author":"Hamaoka","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.jvca.2025.02.009_bib0129","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00000542-199501000-00026","article-title":"Metabolism of a new local anesthetic, ropivicaine, by human hepatic cytochrome P450","volume":"82","author":"Oda","year":"1995","journal-title":"Anesthesiology"},{"key":"10.1053\/j.jvca.2025.02.009_bib0130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0950-3501(98)80029-9","article-title":"The role of the cytochrome P450 system in drug interactions in anaesthesia","volume":"12","author":"Friedericy","year":"1998","journal-title":"Bailleres Clin Anaesthesiol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0131","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.6175","article-title":"Drug-drug interaction potential of mavacamten with midazolam: Combined results from clinical and model-based studies","author":"Merali","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.jvca.2025.02.009_bib0132","unstructured":"United States Food and Drug Administration. Drug development and drug interactions. Table of substrates, inhibitors, and inducers.https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. 2023. [Accessed January 18, 2025]."}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105307702500120X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105307702500120X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T19:39:50Z","timestamp":1744400390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105307702500120X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":132,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S105307702500120X"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2025.02.009","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2025.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}